Jeremy Schreiber, APRN
Psychiatric/Mental Health · Wheeling, WVNPI 1508234147
Payments from drug & device makers
Across 2,808 payments — averaging $612.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$475K
- Alkermes, Inc.$284K
- AbbVie$265K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$197K
- Johnson & Johnson$151K
- Teva Pharmaceuticals USA, Inc.$131K
- plus $217K from 20 others
What the payments were for
- Consulting fees$169,28510%
- Speaking & faculty fees$1,285,03075%
- Travel & lodging$211,49912%
- Food & beverage$53,1183%
- Education$3720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 578 | $475,124 |
| Alkermes, Inc. | 596 | $283,527 |
| AbbVie | 490 | $264,520 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 332 | $196,801 |
| Johnson & Johnson | 245 | $150,571 |
| Teva Pharmaceuticals USA, Inc. | 142 | $131,483 |
| E.r. Squibb & Sons, L.L.C. | 109 | $83,328 |
| Biogen | 74 | $61,180 |
| Axsome Therapeutics, Inc. | 108 | $53,190 |
| Otsuka America Pharmaceutical, Inc. | 36 | $9,730 |
| Vanda Pharmaceuticals Inc. | 40 | $7,963 |
| Novo Nordisk | 14 | $294 |
| Lundbeck LLC | 15 | $285 |
| Supernus Pharmaceuticals, Inc. | 2 | $285 |
| Sage Therapeutics, LLC | 7 | $275 |
| Validus Pharmaceuticals LLC | 1 | $270 |
| Sunovion Pharmaceuticals Inc. | 2 | $102 |
| Corium, LLC | 8 | $94 |
| Zealand Pharma US, Inc. | 1 | $92 |
| Brainsway USA Inc | 1 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Noven Pharmaceuticals, Inc. | 1 | $27 |
| Lilly USA, LLC | 1 | $24 |
| Almatica Pharma LLC | 1 | $18 |
| Eisai Inc. | 1 | $14 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$567,953
- LYBALVI$540,217
- INGREZZA$466,741
- VRAYLAR$255,570
- CAPLYTA$192,082
- ARISTADA INITIO$127,427
- INVEGA SUSTENNA$109,403
- INVEGA TRINZA$108,395
- Austedo XR$96,596
- COBENFY$58,634
- Auvelity$50,388
- SPRAVATO$37,279
- Zurzuvae$36,666
- AUSTEDO$16,907
- UZEDY$16,055
- ABILIFY MAINTENA$9,073
- Fanapt$7,228
- INVEGA$290
- Equetro$270
- QELBREE$264
How this compares
$1,719,304 in reported general payments places this provider in the 95th percentile of 142 psychiatric/mental health providers in West Virginia.
See all psychiatric/mental health providers in West Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 17 | $97,423 |
| SpravatoEsketamine Hcl | 55 | $69,978 |
| RexultiBrexpiprazole | 11 | $15,206 |
| Vilazodone Hcl | 17 | $1,490 |
| Duloxetine Hcl | 66 | $999 |
| Bupropion XlBupropion Hcl | 36 | $519 |
| Buspirone Hcl | 59 | $469 |
| Lamotrigine | 36 | $439 |
| Escitalopram Oxalate | 31 | $315 |
| Trazodone Hcl | 52 | $296 |
| Quetiapine Fumarate | 30 | $242 |
| Mirtazapine | 18 | $205 |
| Ziprasidone Hcl | 11 | $187 |
| Hydroxyzine Pamoate | 19 | $154 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 23 | $141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $131,483 | $97,42317 claims |
| Johnson & JohnsonSpravato | $150,571 | $69,97855 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $9,730 | $15,20611 claims |
| Lilly USA, LLCOlanzapine | $24 | $9614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 142 psychiatric/mental health providers in West Virginia.
Other psychiatric/mental health in Wheeling
- Michael LongwellWheeling$2K
- Kimberly RittenhouseParkersburg$7K
- Michael SkaggsRipley$7K
- Larry RobertsonHuntington$6K
- Gwendolyn HuffmanSummersville$6K
- Summer DevolParkersburg$5K
- Osric Malone-PrioleauSaint Marys$5K
- Mercedes WeikleFort Gay$5K
- Shannon PembertonBarboursville$4K
- Cathy McGeeParkersburg$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.